Clinical trial · no report yet · Phase 3
EXCALIBER-RRMM
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- NCT04975997 ↗
- Active, not recruiting
- Celgene
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 75 | |
| YouTube | 14 | |
| Podcasts | 11 | |
| X videos | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Dexamethasone; Daratumumab; Bortezomib; Iberdomide; Iberdomide; Iberdomide; Dexamethasone; Daratumumab
- Arms
- Daratumumab in combination with Iberdomide and dexamethasone - Dose 1 · Experimental
- Daratumumab in combination with Iberdomide and dexamethasone - Dose 2 · Experimental
- Daratumumab in combination with Iberdomide and dexamethasone - Dose 3 · Experimental
- Daratumumab in combination with dexamethasone and bortezomib · Active comparator
- Enrollment
- 939
- Primary outcomes
- Progression-free Survival (PFS)
- Minimal Residual Disease (MRD) negative Complete Response (CR) at any time
- Sponsor
- Celgene
- Start
- Jun 23, 2022
- Primary completion
- Nov 16, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04975997 · updated Apr 3, 2026
Publications
linked from the registry- Lonial S, Dimopoulos MA, Gavriatopoulou M, Kim K, Min CK, Oriol A, Moreira CCC, Quach H, Qiu L, Xia Z, Schjesvold F, Casas-Aviles I, Xu Y, Hungria V, Seval GC, Fang B, Kyriakou C, Prince HM, Zhuang J, Lin HC, Mateos MV, Spicka I, Maiolino A, Vural F, Basu S, Dytfeld D, Fu C, Ho PJ, Joseph N, Low M, Pour L, Girnius S, Berdeja JG, Otero PR, Cheng Y, Amatangelo M, Hersey S, Kazanecki C, Weisskopf MB, Kyada MJ, Abad PC, Chu S, Morando J, Maciag P, Richardson PG, van de Donk NW; EXCALIBER-RRMM Investigators. Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2026 Sep 25:S1470-2045(26)00450-X. doi: 10.1016/S1470-2045(26)00450-X. Online ahead of print. PubMed 42790445
- Lonial S, Dimopoulos MA, Berdeja JG, Richardson PG, Quach H, Rodriguez-Otero P, Maciag P, Hong K, Amatangelo M, Chen M, van de Donk NWCJ. EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. Future Oncol. 2025 Jun;21(14):1761-1769. doi: 10.1080/14796694.2025.2501920. Epub 2025 May 10. PubMed 40346992